HER2-positive Refractory Advanced Cancer Clinical Trial
Official title:
Safety and Clinical Activity of Lapatinib in Patients With HER2-positive Refractory Advanced Cancer: A Phase II Single Arm Prospective Study
| Verified date | February 2017 |
| Source | Samsung Medical Center |
| Contact | n/a |
| Is FDA regulated | No |
| Health authority | |
| Study type | Interventional |
Although anti-HER2 (human epidermal growth factor receptor 2) therapy is currently approved
for breast, gastric, and gastroesophageal cancers overexpressing the HER2 protein or
amplified for the HER2 gene, HER2 aberrations (gene amplification, gene mutations, and
protein overexpression) are reported in other diverse malignancies. Indeed, about 1-37% of
tumors of the following types harbor HER2 aberrations: bladder, cervix, colon, endometrium,
germ cell, glioblastoma, head and neck, liver, lung, ovarian, pancreas, and salivary duct.
Lapatinib is an orally active, reversible, small molecule TKI that potently inhibits both
ErbB1 and ErbB2 tyrosine kinase activity. Data suggest that a dual ErbB1 and ErbB2 inhibitor
may provide improved therapeutic benefit compared with inhibitors that target only one or
the other receptor.
Therefore, this phase 2 study is designed to evaluated the activity of lapatinib in patients
with HER2-positive refractory cancer.
| Status | Completed |
| Enrollment | 7 |
| Est. completion date | August 21, 2016 |
| Est. primary completion date | January 2016 |
| Accepts healthy volunteers | No |
| Gender | All |
| Age group | 20 Years and older |
| Eligibility |
Inclusion Criteria: - Age > 19 - Written informed consent - ECOG 0-2, - Histologically confirmed HER2-positive Refractory solid tumor(IHC 3+ alone, or IHC 2+ with FISH amplification) and/or specific sensitivity to Lapatinib by Avatar scan that has progressed following standard therapy or that has not responded to standard therapy or for which there is no standard therapy. - The presence of measurable disease as defined by the Response (Evaluation Criteria in Solid Tumors (RECIST) version 1.1) - Adequate organ function Exclusion Criteria: - Uncontrolled symptomatic brain metastasis,Uncontrolled active infection - Uncontrolled systemic illness (DM, CHF, unstable angina, hypertension or arrhythmia) - Prolonged QT interval in ECG (QTc >450 msec) - Pregnant, lactating women - Prior treatment with lapatinib,Malabsorption syndrome, any disease significantly affecting gastrointestinal function, or resection of the stomach or small bowel, or persons unable to swallow oral medication - Prior history of malignancy within 5 years from study entry except for adequately treated basal cell or squamous cell skin cancer or in situ cervical cancer, well-treated thyroid cancer |
| Country | Name | City | State |
|---|---|---|---|
| Korea, Republic of | Samsung Medical Center | Seoul |
| Lead Sponsor | Collaborator |
|---|---|
| Samsung Medical Center |
Korea, Republic of,
| Type | Measure | Description | Time frame | Safety issue |
|---|---|---|---|---|
| Primary | overall response rate | 4 weeks after treatment of lapatinib |